NCT03430895 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03430895
Title	Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract
Recruitment	Completed
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Memorial Sloan Kettering Cancer Center
Indications	bladder adenocarcinoma urethra cancer bladder squamous cell carcinoma renal pelvis squamous cell carcinoma bladder carcinoma urethra squamous cell carcinoma ureter small cell carcinoma urachus cancer ureter carcinoma ureter adenocarcinoma urethra adenocarcinoma renal pelvis carcinoma renal pelvis adenocarcinoma
Therapies	Durvalumab + Tremelimumab
Age Groups:	senior \| adult
Covered Countries	USA

Facility	City	State	Zip	Country	Details
Memorial Sloan Kettering Basking Ridge	Basking Ridge	New Jersey	07920	United States	Details
Memorial Sloan Kettering Commack	Commack	New York	11725	United States	Details
Memoral Sloan Kettering Westchester	Harrison	New York	10604	United States	Details
Memorial Sloan Kettering Cancer Center	New York	New York	10065	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03430895Clinical Trial Detail